[关键词]
[摘要]
葡萄膜炎继发的黄斑水肿(macular edema，ME)是一种葡萄膜炎常见的并发症，可导致非感染性葡萄膜炎(noninfectious uveitis，NIU)患者的视功能障碍。临床上，葡萄膜炎继发ME的治疗仍然非常棘手。目前有多种药物用于治疗葡萄膜炎继发ME，例如皮质类固醇、抗血管内皮生长因子和免疫调节剂等。但是，临床效果报告不一致。近些年来，地塞米松玻璃体内植入剂(intravitreal dexamethasone implant，IDI)是一种广泛应用的皮质类固醇药物。最近的研究表明，IDI有效地改善了葡萄膜炎相关的ME，根据需要通过密切监测和再治疗，这种效应可持续至少6mo。本文就目前国内外关于IDI治疗NIU继发ME进行汇总，并概述相关结果，以期为未来NIU继发ME的诊治提供依据。
[Key word]
[Abstract]
Macular edema(ME)is a typical non-specific complication of uveitis, one of the common causes of visual impairment in patients with non-infectious uveitis(NIU). The treatment of uveitis related ME is still challenging in clinic. Various agents, such as corticosteroids, anti-vascular endothelial growth factors, and immune-modulators, have been used for combating uveitis related ME. However, there is not enough evidence to support the efficacy of any of these agents. Intravitreal dexamethasone implant(IDI, Ozurdex©; Allergan Inc, Irvine, CA)is a widely administered corticosteroid for the long-term management of uveitic ME in certain cases. Recent studies have demonstrated that IDI effectively improves uveitis related ME, and this effect could be sustained for at least six months with close monitoring and retreatment, as needed. Currently, we reviewed major clinical studies about IDI in eyes with NIU and briefly overviewed their results.
[中图分类号]
[基金项目]
兴辽英才计划项目(No.XLYC1807082)
